{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:32:39Z","timestamp":1783632759568,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>A paradoxical increase in GH after oral glucose load (GH-Par) characterizes about one-third of acromegaly patients and is associated with a better response to first-generation somatostatin receptor ligands (fg-SRLs). Pasireotide is typically considered as a second-\/third-line treatment. Here, we investigated the predictive role of GH-Par in pasireotide response and adverse event development.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>we collected a multicenter Italian retrospective cohort of 59 patients treated with pasireotide for at least 3\u00a0months, all having GH profile from OGTT. IGF-1 normalization or at least 30% reduction at the last follow-up visit defined a responder patient.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Considering the entire cohort, median IGF-1 levels before pasireotide (available in 57 patients) were 1.38 times the upper limit of normal (ULN) in patients with large (median size 18\u00a0mm) and invasive (82%) adenomas after failure of fg-SRL treatment. After a 40-month median treatment, pasireotide effectively reduced IGF-1 ULN levels in 41 patients, 37 of whom achieving normalization, and 4 with a\u2009\u2265\u200930% reduction. Thirteen patients were classified as GH-Par. The median pasireotide duration, dosage, and efficacy (9\/12 responder in the GH-Par group and 32\/45 in the GH-NPar) were similar between groups. However, the occurrence of new-onset or worsening glucose metabolism alterations (GMAs) after pasireotide was more frequent in GH-NPar (from 37 to 80%; p\u2009&lt;\u20090.001) compared to GH-Par patients (from 69 to 76%), likely due to the higher prevalence of pre-existing GMAs in the GH-Par group before starting pasireotide (p\u2009=\u20090.038).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The GH-Par does not predict the response to pasireotide in acromegaly but can predict a worse metabolic profile.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s40618-025-02534-3","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T09:54:57Z","timestamp":1737539697000},"page":"1173-1183","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The paradoxical GH response at OGTT does not predict Pasireotide efficacy but matters for glucose metabolism"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4065-4677","authenticated-orcid":false,"given":"G.","family":"Occhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3628-0492","authenticated-orcid":false,"given":"G.","family":"Voltan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9241-2392","authenticated-orcid":false,"given":"S.","family":"Chiloiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4896-5499","authenticated-orcid":false,"given":"A.","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1717-263X","authenticated-orcid":false,"given":"P.","family":"Maffei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1757-5399","authenticated-orcid":false,"given":"F.","family":"Dassie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9065-3886","authenticated-orcid":false,"given":"G.","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9050-0150","authenticated-orcid":false,"given":"G.","family":"Del Sindaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1410-6143","authenticated-orcid":false,"given":"D.","family":"Ferone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5062-9208","authenticated-orcid":false,"given":"F.","family":"Gatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7810-8247","authenticated-orcid":false,"given":"M.","family":"Losa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8779-7283","authenticated-orcid":false,"given":"S.","family":"Cannav\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9396-3815","authenticated-orcid":false,"given":"C.","family":"Scaroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1456-8716","authenticated-orcid":false,"given":"F.","family":"Ceccato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the Pituitary Club of the Italian Society of Endocrinology","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"issue":"1","key":"2534_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","volume":"24","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L, Molitch ME, Samson SL, Strasburger CJ, van der Lely AJ, Melmed S (2021) A Pituitary Society update to acromegaly management guidelines. Pituitary 24(1):1\u201313. https:\/\/doi.org\/10.1007\/s11102-020-01091-7","journal-title":"Pituitary"},{"issue":"2","key":"2534_CR2","doi-asserted-by":"publisher","first-page":"R57","DOI":"10.1530\/EJE-19-0124","volume":"181","author":"J Bollerslev","year":"2019","unstructured":"Bollerslev J, Heck A, Olarescu NC (2019) MANAGEMENT OF ENDOCRINE DISEASE: Individualised management of acromegaly. Eur J Endocrinol 181(2):R57\u2013R71. https:\/\/doi.org\/10.1530\/EJE-19-0124","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2534_CR3","doi-asserted-by":"publisher","first-page":"e532","DOI":"10.1210\/clinem\/dgz187","volume":"105","author":"A Ghajar","year":"2020","unstructured":"Ghajar A, Jones PS, Guarda FJ, Faje A, Tritos NA, Miller KK, Swearingen B, Nachtigall LB (2020) Biochemical Control in Acromegaly With Multimodality Therapies: Outcomes From a Pituitary Center and Changes Over Time. J Clin Endocrinol Metab 105(3):e532\u2013e543. https:\/\/doi.org\/10.1210\/clinem\/dgz187","journal-title":"J Clin Endocrinol Metab"},{"key":"2534_CR4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01524","author":"A Muhammad","year":"2018","unstructured":"Muhammad A, Coopmans EC, Gatto F, Franck SE, Janssen JAMJL, van der Lely AJ, Hofland LJ, Neggers SJCMM (2018) Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/jc.2018-01524","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2534_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/J.BEEM.2022.101684","volume":"36","author":"S Chiloiro","year":"2022","unstructured":"Chiloiro S, Bianchi A, Giampietro A, Pontecorvi A, Raverot G, De Marinis L (2022) Second line treatment of acromegaly: Pasireotide or Pegvisomant? Best Pract Res Clin Endocrinol Metab 36(6):101684. https:\/\/doi.org\/10.1016\/J.BEEM.2022.101684","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"11","key":"2534_CR6","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","volume":"2","author":"MR Gadelha","year":"2014","unstructured":"Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, Pronin V, Raverot G, Shimon I, Lievre KK, Fleck J, Aout M, Pedroncelli AM, Colao A (2014) Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2(11):875\u2013884. https:\/\/doi.org\/10.1016\/S2213-8587(14)70169-X","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2534_CR7","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1530\/EJE-19-0762","volume":"182","author":"A Colao","year":"2020","unstructured":"Colao A, Bronstein MD, Brue T, De Marinis L, Fleseriu M, Guitelman M, Raverot G, Shimon I, Fleck J, Gupta P, Pedroncelli AM, Gadelha MR (2020) Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study. Eur J Endocrinol 182(6):583. https:\/\/doi.org\/10.1530\/EJE-19-0762","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2534_CR8","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s11102-014-0585-6","volume":"18","author":"M Sheppard","year":"2015","unstructured":"Sheppard M, Bronstein MD, Freda P, Serri O, De Marinis L, Naves L, Rozhinskaya L, Hermosillo Res\u00e9ndiz K, Ruffin M, Chen Y, Colao A (2015) Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter Phase III study. Pituitary 18(3):385\u2013394. https:\/\/doi.org\/10.1007\/s11102-014-0585-6","journal-title":"Pituitary"},{"issue":"5","key":"2534_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036411","volume":"7","author":"A Giustina","year":"2012","unstructured":"Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I, Melmed S (2012) Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly. PLoS ONE 7(5):e36411. https:\/\/doi.org\/10.1371\/journal.pone.0036411","journal-title":"PLoS ONE"},{"issue":"June","key":"2534_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.935759","volume":"13","author":"A Mondin","year":"2022","unstructured":"Mondin A, Manara R, Voltan G, Tizianel I, Denaro L, Ferrari M, Barbot M, Scaroni C, Ceccato F (2022) Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne) 13(June):935759. https:\/\/doi.org\/10.3389\/fendo.2022.935759","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2534_CR11","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1530\/eje.0.1330430","volume":"133","author":"M Arosio","year":"1995","unstructured":"Arosio M, Macchelli S, Rossi CM, Casati G, Biella O, Faglia G (1995) Effects of treatment with octreotide in acromegalic patients\u2014a multicenter Italian study. Eur J Endocrinol 133(4):430\u2013439. https:\/\/doi.org\/10.1530\/eje.0.1330430","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2534_CR12","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.tem.2012.11.007","volume":"24","author":"MR Gadelha","year":"2013","unstructured":"Gadelha MR, Kasuki L, Korbonits M (2013) Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab 24(5):238\u2013246. https:\/\/doi.org\/10.1016\/j.tem.2012.11.007","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"2534_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1756-9966-32-40","volume":"32","author":"A Bianchi","year":"2013","unstructured":"Bianchi A, Valentini F, Iuorio R, Poggi M, Baldelli R, Passeri M, Giampietro A, Tartaglione L, Chiloiro S, Appetecchia M, Gargiulo P, Fabbri A, Toscano V, Pontecorvi A, De Marinis L (2013) Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes. J Exp Clin Cancer Res 32(1):40. https:\/\/doi.org\/10.1186\/1756-9966-32-40","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"2534_CR14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1530\/EJE-13-0349","volume":"169","author":"L Kasuki","year":"2013","unstructured":"Kasuki L, Wildemberg LEA, Neto LV, Marcondes J, Takiya CM, Gadelha MR (2013) Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern. Eur J Endocrinol 169(2):217\u2013223. https:\/\/doi.org\/10.1530\/EJE-13-0349","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2534_CR15","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.1365-2265.2011.04163.x","volume":"76","author":"SL Fougner","year":"2012","unstructured":"Fougner SL, Casar-Borota O, Heck A, Berg JP, Bollerslev J (2012) Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol (Oxf) 76(1):96\u2013102. https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04163.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2534_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.mce.2015.09.016","volume":"417","author":"K Kiseljak-Vassiliades","year":"2015","unstructured":"Kiseljak-Vassiliades K, Xu M, Mills TS, Smith EE, Silveira LJ, Lillehei KO, Kerr JM, Kleinschmidt-DeMasters BK, Wierman ME (2015) Differential somatostatin receptor (SSTR) 1\u20135 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors. Mol Cell Endocrinol 417:73\u201383. https:\/\/doi.org\/10.1016\/j.mce.2015.09.016","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"2534_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1365-2265.2011.04286.x","volume":"77","author":"A Heck","year":"2012","unstructured":"Heck A, Ringstad G, Fougner SL, Casar-Borota O, Nome T, Ramm-Pettersen J, Bollerslev J (2012) Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin Endocrinol (Oxf) 77(1):72\u201378. https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04286.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"2534_CR18","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1530\/ERC-16-0356","volume":"23","author":"I Potorac","year":"2016","unstructured":"Potorac I et al (2016) T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocr Relat Cancer 23(11):871\u2013881. https:\/\/doi.org\/10.1530\/ERC-16-0356","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"2534_CR19","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1677\/JME-08-0162","volume":"42","author":"D Ferone","year":"2009","unstructured":"Ferone D, Gatto F, Arvigo M, Resmini E, Boschetti M, Teti C, Esposito D, Minuto F (2009) The clinical\u2013molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology. J Mol Endocrinol 42(5):361\u2013370. https:\/\/doi.org\/10.1677\/JME-08-0162","journal-title":"J Mol Endocrinol"},{"issue":"3","key":"2534_CR20","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1111\/jcmm.13440","volume":"22","author":"E Venegas-Moreno","year":"2018","unstructured":"Venegas-Moreno E, Vazquez-Borrego MC, Dios E, Gros-Herguido N, Flores-Martinez A, Rivero-Cort\u00e9s E, Madrazo-Atutxa A, Jap\u00f3n MA, Luque RM, Casta\u00f1o JP, Cano DA, Soto-Moreno A (2018) Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly. J Cell Mol Med 22(3):1640\u20131649. https:\/\/doi.org\/10.1111\/jcmm.13440","journal-title":"J Cell Mol Med"},{"issue":"2","key":"2534_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1530\/EJE-15-0832","volume":"174","author":"D Iacovazzo","year":"2016","unstructured":"Iacovazzo D, Carlsen E, Lugli F, Chiloiro S, Piacentini S, Bianchi A, Giampietro A, Mormando M, Clear AJ, Doglietto F, Anile C, Maira G, Lauriola L, Rindi G, Roncaroli F, Pontecorvi A, Korbonits M, De Marinis L (2016) Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur J Endocrinol 174(2):241\u2013250. https:\/\/doi.org\/10.1530\/EJE-15-0832","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2534_CR22","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1210\/jc.2018-01360","volume":"104","author":"C Scaroni","year":"2019","unstructured":"Scaroni C, Albiger N, Daniele A, Dassie F, Romualdi C, Vazza G, Regazzo D, Ferra\u00f9 F, Barresi V, Maffeis V, Gardiman MP, Cannav\u00f2 S, Maffei P, Ceccato F, Losa M, Occhi G (2019) Paradoxical GH increase during OGTT is associated with first-generation somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 104(3):856\u2013862. https:\/\/doi.org\/10.1210\/jc.2018-01360","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2534_CR23","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1210\/jc.2018-00975","volume":"104","author":"K Mukai","year":"2019","unstructured":"Mukai K, Otsuki M, Tamada D, Kitamura T, Hayashi R, Saiki A, Goto Y, Arita H, Oshino S, Morii E, Saitoh Y, Shimomura I (2019) Clinical characteristics of acromegalic patients with paradoxical GH response to oral glucose load. J Clin Endocrinol Metab 104(5):1637\u20131644. https:\/\/doi.org\/10.1210\/jc.2018-00975","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2534_CR24","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1530\/EJE-21-0324","volume":"185","author":"V Atquet","year":"2021","unstructured":"Atquet V, Alexopoulou O, Maiter D (2021) Characteristics and treatment responsiveness of patients with acromegaly and a paradoxical GH increase to oral glucose load. Eur J Endocrinol 185(2):313\u2013321. https:\/\/doi.org\/10.1530\/EJE-21-0324","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2534_CR25","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/cen.14946","volume":"99","author":"S Ruiz","year":"2023","unstructured":"Ruiz S, Gil J, Biagetti B, Venegas E, C\u00e1mara R, Garcia-Centeno R, G\u00e1lvez M-\u00c1, Pic\u00f3 A, Maraver S, Gonz\u00e1lez I, Abell\u00e1n P, Trincado P, Herrera M, Olvera P, Xifra G, Bernabeu I, Serra-Soler G, Azriel S, Garc\u00eda L, Carvalho D, Jord\u00e0 M, Valassi E, Puig J, Puig-Domingo M (2023) Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly. Clin Endocrinol (Oxf) 99(4):378\u2013385. https:\/\/doi.org\/10.1111\/cen.14946","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"2534_CR26","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/S40618-023-02275-1","volume":"47","author":"C Urbani","year":"2024","unstructured":"Urbani C, Dassie F, Zampetti B, Mioni R, Maffei P, Cozzi R, Bogazzi F (2024) Real-life data of Pasireotide LAR in acromegaly: a long-term follow-up. J Endocrinol Invest 47(7):1733\u20131741. https:\/\/doi.org\/10.1007\/S40618-023-02275-1","journal-title":"J Endocrinol Invest"},{"key":"2534_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/S40618-023-02186-1","author":"G Corica","year":"2024","unstructured":"Corica G, Pirchio R, Milioto A, Nista F, Arecco A, Mattioli L, Auriemma RS, Cocchiara F, Pivonello R, Colao A, Ferone D, Gatto F (2024) Pasireotide effects on biochemical control and glycometabolic profile in acromegaly patients switched from combination therapies or unconventional dosages of somatostatin analogs. J Endocrinol Invest. https:\/\/doi.org\/10.1007\/S40618-023-02186-1","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"2534_CR28","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/S12020-022-03158-W","volume":"78","author":"S Chiloiro","year":"2022","unstructured":"Chiloiro S, Costa D, Lauretta R, Mercuri V, Sbardella E, Samperi I, Appetecchia M, Bianchi A, Giampietro A, Gargiulo P, Isidori AM, Poggi M, Pontecorvi A, De Marinis L (2022) Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly. Endocrine 78(2):343\u2013353. https:\/\/doi.org\/10.1007\/S12020-022-03158-W","journal-title":"Endocrine"},{"issue":"3","key":"2534_CR29","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1007\/S12020-021-02711-3","volume":"73","author":"S Chiloiro","year":"2021","unstructured":"Chiloiro S, Giampietro A, Visconti F, Rossi L, Donfrancesco F, Fleseriu CM, Mirra F, Pontecorvi A, Giustina A, Fleseriu M, De Marinis L, Bianchi A (2021) Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant. Endocrine 73(3):658\u2013666. https:\/\/doi.org\/10.1007\/S12020-021-02711-3","journal-title":"Endocrine"},{"issue":"2","key":"2534_CR30","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1530\/EJE-20-0767","volume":"184","author":"S Chiloiro","year":"2021","unstructured":"Chiloiro S, Giampietro A, Mirra F, Donfrancesco F, Tartaglione T, Mattogno PP, Angelini F, Liverana L, Gessi M, Carmelo A, Rindi G, Giustina A, Fleseriu M, Pontecorvi A, de Marinis L, Bianchi A (2021) Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response. Eur J Endocrinol 184(2):217\u2013229. https:\/\/doi.org\/10.1530\/EJE-20-0767","journal-title":"Eur J Endocrinol"},{"key":"2534_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/S40618-023-02138-9","author":"F Ceccato","year":"2023","unstructured":"Ceccato F, Vedolin CK, Voltan G, Antonelli G, Barbot M, Basso D, Regazzo D, Scaroni C, Occhi G (2023) Paradoxical GH increase after oral glucose load in subjects with and without acromegaly. J Endocrinol Invest. https:\/\/doi.org\/10.1007\/S40618-023-02138-9","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"2534_CR32","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, Initiative STROBE (2008) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61(4):344\u2013349. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.008","journal-title":"J Clin Epidemiol"},{"key":"2534_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s00701-017-3396-5","author":"F Ceccato","year":"2018","unstructured":"Ceccato F, Regazzo D, Barbot M, Denaro L, Emanuelli E, Borsetto D, Rolma G, Alessio L, Gardiman MP, Lombardi G, Albiger N, D\u2019Avella D, Scaroni C (2018) Early recognition of aggressive pituitary adenomas: a single-centre experience. Acta Neurochir (Wien). https:\/\/doi.org\/10.1007\/s00701-017-3396-5","journal-title":"Acta Neurochir (Wien)"},{"issue":"3","key":"2534_CR34","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1210\/JC.2017-01844","volume":"103","author":"SH Park","year":"2018","unstructured":"Park SH, Ku CR, Moon JH, Kim EH, Kim SH, Lee EJ (2018) Age- and Sex-Specific Differences as Predictors of Surgical Remission Among Patients With Acromegaly. J Clin Endocrinol Metab 103(3):909\u2013916. https:\/\/doi.org\/10.1210\/JC.2017-01844","journal-title":"J Clin Endocrinol Metab"},{"key":"2534_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/FENDO.2024.1348972","author":"S G\u0103loiu","year":"2024","unstructured":"G\u0103loiu S, Toma ID, T\u0103nasie DI, B\u0103rbulescu A, Baciu I, Niculescu DA, Trif\u0103nescu RA, C\u0103p\u0103\u0163\u00een\u0103 C, Radian \u015e, Poian\u0103 C (2024) High mortality risk among women with acromegaly still persists. Front Endocrinol (Lausanne). https:\/\/doi.org\/10.3389\/FENDO.2024.1348972","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2534_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/J.GHIR.2022.101501","author":"H D\u00fc\u011fer","year":"2022","unstructured":"D\u00fc\u011fer H, Bostan H, Deryol HY, \u0130mga NN, U\u00e7an B, \u00c7alapkulu M, Hep\u015fen S, Akhanl\u0131 P, G\u00fcl \u00dc, Sencar ME, \u00c7akal E, \u00d6zdemir \u015e, K\u0131z\u0131lg\u00fcl M (2022) Paradoxical GH increase during oral glucose load may predict overall remission in acromegalic patients. Growth Horm IGF Res. https:\/\/doi.org\/10.1016\/J.GHIR.2022.101501","journal-title":"Growth Horm IGF Res"},{"key":"2534_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/S11102-022-01272-6","author":"O Faria","year":"2022","unstructured":"Faria O, Miranda RL, de Azeredo Lima CH, Guterres A, Ventura N, Barbosa MA, da Silva Camacho AH, Lamback EB, Andreiuolo F, Chimelli L, Kasuki L, Gadelha MR (2022) Characterization of sporadic somatotropinomas with high GIP receptor expression. Pituitary. https:\/\/doi.org\/10.1007\/S11102-022-01272-6","journal-title":"Pituitary"},{"issue":"5","key":"2534_CR38","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1530\/EJE-16-0831","volume":"176","author":"D Regazzo","year":"2017","unstructured":"Regazzo D, Losa M, Albiger NM, Terreni MR, Vazza G, Ceccato F, Emanuelli E, Denaro L, Scaroni C, Occhi G (2017) The GIP\/GIPR axis is functionally linked to GH-secretion increase in a significant proportion of gsp-somatotropinomas. Eur J Endocrinol 176(5):543\u2013553. https:\/\/doi.org\/10.1530\/EJE-16-0831","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2534_CR39","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/j.1365-2826.2011.02155.x","volume":"23","author":"G Occhi","year":"2011","unstructured":"Occhi G, Losa M, Albiger N, Trivellin G, Regazzo D, Scanarini M, Monteserin-Garcia JL, Fr\u00f6hlich B, Ferasin S, Terreni MR, Fassina A, Vitiello L, Stalla G, Mantero F, Scaroni C (2011) The glucose-dependent insulinotropic polypeptide receptor is overexpressed amongst GNAS1 mutation-negative somatotropinomas and drives growth hormone (GH)-promoter activity in GH3 cells. J Neuroendocrinol 23(7):641\u2013649. https:\/\/doi.org\/10.1111\/j.1365-2826.2011.02155.x","journal-title":"J Neuroendocrinol"},{"issue":"5","key":"2534_CR40","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1507\/endocrj.50.643","volume":"50","author":"M Umahara","year":"2003","unstructured":"Umahara M, Okada S, Ohshima K, Mori M (2003) Glucose-dependent insulinotropic polypeptide induced growth hormone secretion in acromegaly. Endocr J 50(5):643\u2013650. https:\/\/doi.org\/10.1507\/endocrj.50.643","journal-title":"Endocr J"},{"issue":"5","key":"2534_CR41","doi-asserted-by":"publisher","first-page":"658","DOI":"10.2165\/00003495-198938050-00002","volume":"38","author":"PE Battershill","year":"1989","unstructured":"Battershill PE, Clissold SP (1989) Octreotide Drugs 38(5):658\u2013702. https:\/\/doi.org\/10.2165\/00003495-198938050-00002","journal-title":"Octreotide Drugs"},{"key":"2534_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00358","author":"F Ferra\u00f9","year":"2018","unstructured":"Ferra\u00f9 F, Albani A, Ciresi A, Giordano C, Cannav\u00f2 S (2018) Diabetes secondary to acromegaly: physiopathology clinical features and effects of treatment. Front Endocrinol (Lausanne). https:\/\/doi.org\/10.3389\/fendo.2018.00358","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"5","key":"2534_CR43","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s11102-020-01055-x","volume":"23","author":"M Barbot","year":"2020","unstructured":"Barbot M, Regazzo D, Mondin A, Zilio M, Lizzul L, Zaninotto M, Plebani M, Arnaldi G, Ceccato F, Scaroni C (2020) Is pasireotide-induced diabetes mellitus predictable? A pilot study on the effect of a single dose of pasireotide on glucose homeostasis. Pituitary 23(5):534\u2013542. https:\/\/doi.org\/10.1007\/s11102-020-01055-x","journal-title":"Pituitary"},{"issue":"9","key":"2534_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms23095217","volume":"23","author":"M Barbot","year":"2022","unstructured":"Barbot M, Mondin A, Regazzo D, Guarnotta V, Basso D, Giordano C, Scaroni C, Ceccato F (2022) Incretin Response to Mixed Meal Challenge in Active Cushing\u2019s Disease and after Pasireotide Therapy. Int J Mol Sci 23(9):1\u201313. https:\/\/doi.org\/10.3390\/ijms23095217","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2534_CR45","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1530\/EC-20-0361","volume":"9","author":"MR Gadelha","year":"2020","unstructured":"Gadelha MR, Gu F, Bronstein MD, Brue TC, Fleseriu M, Shimon I, van der Lely AJ, Ravichandran S, Kandra A, Pedroncelli AM, Colao AAL (2020) Risk factors and management of pasireotide-associated hyperglycemia in acromegaly. Endocr Connect 9(12):1178\u20131190. https:\/\/doi.org\/10.1530\/EC-20-0361","journal-title":"Endocr Connect"},{"issue":"2","key":"2534_CR46","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s11102-012-0396-6","volume":"16","author":"D Niculescu","year":"2013","unstructured":"Niculescu D, Purice M, Coculescu M (2013) Insulin-like growth factor-I correlates more closely than growth hormone with insulin resistance and glucose intolerance in patients with acromegaly. Pituitary 16(2):168\u2013174. https:\/\/doi.org\/10.1007\/s11102-012-0396-6","journal-title":"Pituitary"},{"issue":"10","key":"2534_CR47","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3275\/8964","volume":"36","author":"K Mori","year":"2013","unstructured":"Mori K, Iwasaki Y, Kawasaki-Ogita Y, Honjo S, Hamamoto Y, Tatsuoka H, Fujimoto K, Ikeda H, Wada Y, Takahashi Y, Takahashi J, Koshiyama H (2013) Improvement of insulin resistance following transsphenoidal surgery in patients with acromegaly: correlation with serum IGF-I levels. J Endocrinol Invest 36(10):853\u2013859. https:\/\/doi.org\/10.3275\/8964","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2534_CR48","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11102-013-0471-7","volume":"17","author":"O Alexopoulou","year":"2014","unstructured":"Alexopoulou O, Bex M, Kamenicky P, Mvoula AB, Chanson P, Maiter D (2014) Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary 17(1):81\u201389. https:\/\/doi.org\/10.1007\/s11102-013-0471-7","journal-title":"Pituitary"},{"issue":"6","key":"2534_CR49","doi-asserted-by":"publisher","first-page":"R261","DOI":"10.1530\/EJE-20-1448","volume":"184","author":"M Hage","year":"2021","unstructured":"Hage M, Janot C, Salenave S, Chanson P, Kamenick\u00fd P (2021) MANAGEMENT OF ENDOCRINE DISEASE: Etiology and outcome of acromegaly in patients with a paradoxical GH response to glucose. Eur J Endocrinol 184(6):R261\u2013R268. https:\/\/doi.org\/10.1530\/EJE-20-1448","journal-title":"Eur J Endocrinol"},{"key":"2534_CR50","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-023-01360-1","author":"A Giustina","year":"2023","unstructured":"Giustina A et al (2023) Consensus on criteria for acromegaly diagnosis and remission. Pituitary. https:\/\/doi.org\/10.1007\/s11102-023-01360-1","journal-title":"Pituitary"},{"key":"2534_CR51","doi-asserted-by":"publisher","DOI":"10.1210\/CLINEM\/DGAE410","author":"M Losa","year":"2024","unstructured":"Losa M, Garbin E, Calcagnile R, Voltan G, Ceccato F, Scaroni C, Occhi G, Mortini P (2024) The Preoperative Paradoxical GH Response to Oral Glucose Load Predicts a low Risk of Recurrence in Acromegaly. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/CLINEM\/DGAE410","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02534-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-025-02534-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02534-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T05:50:31Z","timestamp":1746251431000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-025-02534-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":51,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["2534"],"URL":"https:\/\/doi.org\/10.1007\/s40618-025-02534-3","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]},"assertion":[{"value":"13 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Filippo Ceccato: PhD grant by Novartis Pharma. Pietro Maffei: consultancy fees or Principal Investigator by Recordati, Pfizer, Camurus. Diego Ferone: honoraria for lectures or advisory boards from Recordati, Ipsen, Novartis-AAA, as well as research grants from Camurus and Pfizer. Federico Gatto: honoraria for lectures, manuscript writing, educational events, and consultancy from Pfizer and Recordati. All other authors declare that they have no conflicts of interest that might be perceived as influencing the impartiality of the reported research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}